\_

Watanabe H., Ishibashi K., Mano H., Kitamoto S., Sato N., Hoshiba K., Kato M., Matsuzawa F., Takeuchi Y., Shirai T., Ishikawa S., Morioka Y. , Imagawa T., Sakaguchi K., Yonezawa S., Kon S. and Fujita Y.  

Mutant p53-expressing cells undergo necroptosis via cell competition with the neighboring normal epithelial cells.

Cell Rep. 23, 3721-3729, (2018)

 

Morioka Y., Nam JM. and Ohashi T.  

Nik-related kinase regulates trophoblast proliferation and placental development by modulating AKT phosphorylation.

PLoS ONE 12, e0171503, (2017)

 

Tatematsu M., Yoshida R., Morioka Y., Ishii N., Funami K., Watanabe A., Saeki K., Seya T. and Matsumoto M.

Raftlin controls Lipopolysaccharide-induced TLR4 internalization and TICAM-1 signaling in a cell type-specific manner.

J. Immunol. 196, 3865-3876, (2016)

 

Oshiumi H., Miyashita M., Okamoto M., Morioka Y., Okabe M., Matsumoto M. and Seya T.

DDX60 is involved in RIG-I-dependent and -independent antiviral responses and its function is attenuated by virus-induced EGF receptor activation.

Cell Rep. 11, 1193-1207, (2015)

 

Kasamatsu J., Azuma M., Oshiumi H., Morioka Y., Okabe M., Ebihara T., Matsumoto M. and Seya T.

INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinic-polycytidylic acid-stimulated accessory cells.

J. Immunol. 193, 5199-207, (2014)

 

Morioka Y., Fujihara Y. and Okabe M.

Generation of precise point mutation mice by footprintless genome modification.

Genesis 52, 68-77, (2014)

 

Kanatsu-Shinohara M., Kato-Itoh M., Ikawa M., Takehashi M., Sanbo M., Morioka Y., Tanaka T., Morimoto H., Hirabayashi M. and Shinohara T.

Homologous Recombination in Rat Germline Stem Cells.

Biol. Reprod. 85, 208-217, (2011)

 

Suga T., Kimura E., Morioka Y., Ikawa M., Li S., Uchino K., Uchida Y., Yamashita S., Maeda Y., Chamberlain JS. and Uchino M.

Muscle fiber type-predominant promoter activity in lentiviral-mediated transgenic mouse.

PLoS ONE 6, e16908, (2011)

 

Kumasawa K., Ikawa M., Kidoya H., Hasuwa H., Saito-Fujita S., Morioka Y., Takakura N., Kimura T. and Okabe M.

Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Proc. Natl. Acad. Sci. USA. 108, 1451-1455, (2011)

 

Shibukawa Y., Yamazaki N., Kumasawa K., Daimon E., Tajiri M., Okada (Morioka) Y., Ikawa M. and Wada Y.

Calponin 3 Regulates Actin Cytoskeleton Rearrangement in Trophoblastic Cell Fusion.

Mol. Biol. Cell 21, 3973-3984, (2010)

 

Morioka Y., Isotani A., Oshima RG., Okabe M. and Ikawa M.

Placenta-specific gene activation and inactivation using integrase-defective lentiviral vectors with the Cre/LoxP system.

Genesis 47, 793-798, (2009)

 

Ohta H., Ohinata Y., Ikawa M., Morioka Y., Sakaide Y., Saitou M., Kanagawa O. and Wakayama T.

Male Germline and Embryonic Stem Cell Lines from NOD Mice: Efficient Derivation of GS Cells from a Nonpermissive Strain for ES Cell Derivation.

Biol. Reprod. 81, 1147-1153, (2009)

 

Yao X., Morishige T., Eto Y., Watanabe H., Okada (Morioka) Y., Mizuguchi H., Mukai Y., Okada N. and Nakagawa S.

Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.

Gene Ther. 16, 1395-1404, (2009)

 

Okada (Morioka) Y., Ueshin Y., Hasuwa H., Takumi K., Okabe M. and Ikawa M.  

Targeted gene modification in mouse ES cells using integrase-defective lentiviral vectors.

Genesis 47, 217-223, (2009)

 

Yao X., Yoshioka Y., Eto Y., Morishige T., Okada (Morioka) Y., Mizuguchi H., Mukai Y., Okada N. and Nakagawa S.

TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection.

Biochem. Biophys. Res. Commun. 362, 419-424, (2007)

 

ciXjT

ٔՓٓIȈ`qZp̊JƂ̗Lp]

wG 128 (7) : 1007-1011 (2008)

 

Gao JQ., Eto Y., Yoshioka Y., Sekiguchi F., Kurachi S., Morishige T., Yao X., Watanabe H., Asavatanabodee R., Sakurai F., Mizuguchi H., Okada (Morioka) Y., Mukai Y., Tsutsumi Y., Mayumi T., Okada N. and Nakagawa S.

Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration

J. Controll. Release 122, 102-110, (2007)

 

Okada (Morioka) Y., Ueshin Y., Isotani A., Saito-Fujita T., Nakashima H., Kimura K., Mizoguchi A., Oh-Hora M., Mori Y., Ogata M., Oshima RG., Okabe M. and Ikawa M.

Complementation of placental defects and embryonic lethality by trophoblast-specific lentiviral gene transfer.

Nat. Biotechnol. 25, 233-237, (2007)

 

Okada N., Sasaki A., Niwa M., Okada (Morioka) Y., Hatanaka Y., Tani Y., Mizuguchi H., Nakagawa S., Fujita T. and Yamamoto A.

Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector.

Cancer Gene Ther. 13, 393-405, (2006)

 

Okada (Morioka) Y., Okada N., Mizuguchi H, Hayakawa T., Nakagawa S. and Mayumi T.

Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.

Cancer Gene Ther. 12, 608-616, (2005)

 

Okada N., Mori N., Koretomo R., Okada (Morioka) Y., Nakayama T., Yoshie O., Mizuguchi H., Hayakawa T., Nakagawa S., Mayumi T., Fujita T. and Yamamoto A.

Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.

Gene Ther. 12, 129-139, (2005)

 

Okada N., Iiyama S., Okada (Morioka) Y., Mizuguchi H., Hayakawa T., Nakagawa S., Mayumi T., Fujita T. and Yamamoto A.

Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12

Cancer Gene Ther. 12, 72-83, (2005)

 

Okada N., Gao JQ., Sasaki A., Niwa M., Okada (Morioka) Y., Nakayama T., Yoshie O., Mizuguchi H., Hayakawa T., Fujita T., Yamamoto A., Tsutsumi Y., Mayumi T. and Nakagawa S.

Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy.

Biochem. Biophys. Res. Commun. 317, 68-76, (2004)

 

Okada (Morioka) Y., Okada N., Mizuguchi H., Takahashi K., Hayakawa T., Mayumi T. and Mizuno N.

Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma.

Biochim. Biophys. Acta. 1670, 172-180, (2004)

 

Okada N., Masunaga Y., Okada (Morioka) Y., Mizuguchi H., Iiyama S., Mori N., Sasaki A., Nakagawa S., Mayumi T., Hayakawa T., Fujita T. and Yamamoto A.

Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.

Gene Ther. 10, 1891-1902, (2003)

 

Okada N., Masunaga Y., Okada (Morioka) Y., Iiyama S., Mori N., Tsuda T., Matsubara A., Mizuguchi H., Hayakawa T., Fujita T. and Yamamoto A.

Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors.

Cancer Gene Ther. 10, 421-431, (2003)

 

Okada (Morioka) Y., Okada N., Mizuguchi H., Hayakawa T., Mayumi T. and Mizuno N.

An investigation of adverse effects caused by the injection of high-dose TNFalpha-expressing adenovirus vector into established murine melanoma

Gene Ther. 10, 700-705, (2003)

 

Okada (Morioka) Y., Okada N., Nakagawa S., Mizuguchi H., Takahashi K., Mizuno N., Fujita T., Yamamoto A., Hayakawa T. and Mayumi T.

Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors.

Jpn. J. Cancer Res. 93, 436-444, (2002)

 

Okada (Morioka) Y., Okada N., Nakagawa S., Mizuguchi H., Kanehira M., Nishino N., Takahashi K., Mizuno N., Hayakawa T. and Mayumi T.

Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors.

Cancer Lett. 177, 57-63, (2002)

 

Okada N., Saito T., Masunaga Y., Tsukada Y., Nakagawa S., Mizuguchi H., Mori K., Okada (Morioka) Y., Fujita T., Hayakawa T., Mayumi T. and Yamamoto A.

Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate anti-tumor vaccine efficacy and maturation of murine dendritic cells.

Cancer Res. 61, 7913-7919, (2001)

 

Mizuguchi H., Nakagawa T., Morioka Y., Imazu S., Nakanishi M., Kondo T., Hayakawa T. and Mayumi T.

Cytoplasmic gene expression system enhances the efficiency of cationic liposome-mediated in vivo gene transfer into mouse brain.

Biochem. Biophys. Res. Commun. 234, 15-18, (1997)